Literature DB >> 17410021

Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer.

Katsuyuki Hotta, Keitaro Matsuo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17410021     DOI： 10.1097/JTO.0b013e31802bb010

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.

Authors:  Satoru Senoo; Kiichiro Ninomiya; Katsuyuki Hotta; Katsuyuki Kiura
Journal:  Int J Clin Oncol       Date:  2019-03-07       Impact factor: 3.402

2.  Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.

Authors:  Kiichiro Ninomiya; Katsuyuki Hotta; Akiko Hisamoto-Sato; Eiki Ichihara; Hiroko Gotoda; Daisuke Morichika; Tomoki Tamura; Hiroe Kayatani; Daisuke Minami; Toshio Kubo; Masahiro Tabata; Mitsune Tanimoto; Katsuyuki Kiura
Journal:  Int J Clin Oncol       Date:  2015-06-21       Impact factor: 3.402

3.  Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials.

Authors:  Ayako Matsuda; Kazue Yamaoka; Toshiro Tango
Journal:  Exp Ther Med       Date:  2011-10-18       Impact factor: 2.447

4.  Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Nagio Takigawa; Shoichi Kuyama; Yoshihiko Segawa; Toshiro Yonei; Kenichi Gemba; Keisuke Aoe; Takuo Shibayama; Keisuke Matsuo; Haruhito Kamei; Yoshiro Fujiwara; Akihiko Bessho; Tomonori Moritaka; Keisuke Sugimoto; Masahiro Tabata; Hiroshi Ueoka; Mitsune Tanimoto
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-11       Impact factor: 4.553

Review 5.  Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Yoshiro Fujiwara; Nagio Takigawa; Akiko Hisamoto; Eiki Ichihara; Masahiro Tabata; Mitsune Tanimoto
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

6.  A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer.

Authors:  Vinzenz Kroeber; Sylke Nagel; Wolfgang Schuette; Thomas Blankenburg
Journal:  Case Rep Oncol       Date:  2014-07-05

Review 7.  Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.

Authors:  Katsuyuki Hotta; Yuka Kato; Natasha Leighl; Nagio Takigawa; Rabab Mohamed Gaafar; Hiroe Kayatani; Taizo Hirata; Kadoaki Ohashi; Toshio Kubo; Masahiro Tabata; Mitsune Tanimoto; Katsuyuki Kiura
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.

Authors:  Nobuaki Ochi; Hiromichi Yamane; Katsuyuki Hotta; Hiromi Fujii; Hideko Isozaki; Yoshihiro Honda; Tomoko Yamagishi; Toshio Kubo; Mitsune Tanimoto; Katsuyuki Kiura; Nagio Takigawa
Journal:  Drug Des Devel Ther       Date:  2014-12-03       Impact factor: 4.162

Review 9.  Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Authors:  Katsuyuki Hotta; Nobukazu Fujimoto
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.